Prostaglandin E(2) and myocarditis; friend or foe?
Recommended Citation
Bryson TD, and Harding P. Prostaglandin E(2) and myocarditis; friend or foe? Biochem Pharmacol 2023; 217:115813.
Document Type
Article
Publication Date
11-1-2023
Publication Title
Biochemical pharmacology
Abstract
This review article summarizes the role of prostaglandin E(2) (PGE(2)) and its receptors (EP1-EP4) as it relates to the inflammatory cardiomyopathy, myocarditis. During the COVID-19 pandemic, the onset of myocarditis in a subset of patients prompted a debate on the use of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, which act to inhibit the actions of prostaglandins. This review aims to further understanding of the role of PGE(2) in the pathogenesis or protection of the myocardium in myocarditis. Inflammatory cardiomyopathies encompass a broad spectrum of disorders, all characterized by cardiac inflammation. Therefore, for the purpose of this review, the authors have placed particular emphasis on etiologies of myocarditis where effects of PGE(2) have been documented.
Medical Subject Headings
Humans; Myocarditis; Pandemics; Receptors, Prostaglandin E, EP4 Subtype; Dinoprostone; Prostaglandins
PubMed ID
37722627
Volume
217
First Page
115813
Last Page
115813
